Asthma Therapeutics Trends up to 2020 in Major Developed Markets 1 | Page 2

[email protected] Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion. Scope of the report – The report covers and includes – - An introduction to asthma, including discussion of disease epidemiology, etiology pathophysiology, symptoms, diagnosis, and treatment, with clinical data for drugs featured in the current treatment algorithm discussed in detail. - In-depth analysis of the current marketed products landscape, including product profiles of the main drugs used and heat maps that compare their safety and efficacy parameters. - Comprehensive analysis of the asthma pipeline by phase of development, molecule type, and molecular target and novelty, and comparative analysis of the most promising late-stage pipeline drugs, as well as heat maps and a competitor matrix that compares safety and efficacy parameters. Get Sample of “Asthma Therapeutics in Major Developed Markets to 2020 Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations” Market Research Report at http://www.marketreportsworld.com/enquiry/request-sample/10070377 - Additional in-depth analysis of the asthma clinical trials landscape, including trends in size, duration and failure rate. - Forecast projections for the asthma market to 2020, including analysis of the global [phone] www.marketreportsworld.com [email protected]